Active Stocks
Thu Mar 28 2024 15:59:33
  1. Tata Steel share price
  2. 155.90 2.00%
  1. ICICI Bank share price
  2. 1,095.75 1.08%
  1. HDFC Bank share price
  2. 1,448.20 0.52%
  1. ITC share price
  2. 428.55 0.13%
  1. Power Grid Corporation Of India share price
  2. 277.05 2.21%
Business News/ Companies / Syngene Q3 profit up 31% to Rs58.8 crore
BackBack

Syngene Q3 profit up 31% to Rs58.8 crore

Profit notched up on a 23% increase in revenue to `280.4 crore from `227.6 crore

Shares of Syngene gained 2.17% to close at `367.60 on BSE, while the benchmark Sensex declined 0.41% to 23962.21 points. Premium
Shares of Syngene gained 2.17% to close at `367.60 on BSE, while the benchmark Sensex declined 0.41% to 23962.21 points.

Hyderabad: Syngene International Ltd, the contract research services arm of India’s biggest biopharmaceutical firm Biocon Ltd, on Thursday announced a 31% increase in net profit for the quarter ended 31 December, led by sustained momentum across its key verticals including dedicated centres, discovery services as well as development and manufacturing services.

Profit rose to 58.8 crore in the fiscal third quarter, from 44.8 crore in the year-ago period. The profit was notched up on a 23% increase in revenue to 280.4 crore from 227.6 crore.

Syngene said it cleared a US Food and Drug Administration audit of its clinical development facility in Benguluru during the third quarter.

Syngene has now successfully cleared five audits by the US regulator in the space of the last 30 months, the company said.

Syngene said it will be pumping around $200 million on capital expenditure over the next three-and-a-half to four years as part of a broader plan to evolve from a contract research organisation into a contract research and manufacturing services company with commercial-scale production capabilities.

The company is investing around $100 million on setting up a new unit in Mengaluru over the next three to four years to support large-scale manufacturing requirements of its clientele. The remaining will go into investments in a new research centre, a formulation centre and a large molecules manufacturing unit at its Bengaluru facility.

“Phase 1 of our new research centre is nearing completion, and will add significant capacities underpinning future growth," said Peter Bains, executive director and chief executive officer, in a statement.

“We continue to enhance and expand our service offerings to align with growing client requirements," he said.

Bains said the company is on track to achieve its $250 million sales target by FY18.

Phase 1 of the research centre comprises of 50,000 sq. feet of lab space, scheduled to be commissioned in Q1 FY17, the company said.

When fully commissioned, this centre will be a 200,000 sq. ft versatile, state-of-the-art research facility and will support integrated discovery programmes in chemistry and biology, the company added.

In the year ended March 2015, Syngene had 221 clients, including 8 of the top 10 global pharma companies.

As of 30 September, Biocon held a 74.55% stake in Syngene.

Shares of Syngene gained 2.17% to close at 367.60 on BSE, while the benchmark Sensex declined 0.41% to 23962.21 points.

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Corporate news and Updates on Live Mint. Download The Mint News App to get Daily Market Updates & Live Business News.
More Less
Published: 21 Jan 2016, 10:19 PM IST
Next Story footLogo
Recommended For You
Switch to the Mint app for fast and personalized news - Get App

Chat with MintGenie